Generic drug
Chlorpheniramine / hydrocodone price, strengths & recalls
Pharmacies pay $54.69 for 115 mL of Chlorpheniramine / hydrocodone 1.6 mg/mL / 2 mg/mL (12 hr) extended release suspension this week. 2 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on February 17, 2026.
Generic- Fair cash price
- $73.39
- Strengths
- 1
- Makers
- 2
- Updated
- Nov 11
Chlorpheniramine / hydrocodone price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 1.6 mg/mL / 2 mg/mL (12 hr) extended release suspension | $0.4756 | $54.69 / 115 mL |
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Chlorpheniramine / hydrocodone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension safely and effectively. See full prescribing information for Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension, for oral administration, CII Initial U.S. Approval: 1987
WARNING: ADDICTION,
ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL
INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE
WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL;
NEONATAL OPIOID WITHDRAWAL SYNDROME
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME
Addiction, Abuse, and Misuse
Hydrocodone Polistirex and Chlorpheniramine Polistirex exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Reserve Hydrocodone Polistirex and Chlorpheniramine Polistirex for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient's risk prior to prescribing Hydrocodone Polistirex and Chlorpheniramine Polistirex, prescribe Hydrocodone Polistirex and Chlorpheniramine Polistirex for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addition or abuse, and refill only after reevaluation of the need for continued treatment. [see Warnings and Precautions (5.1)]
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of Hydrocodone Polistirex and Chlorpheniramine Polistirex. Monitor for respiratory depression, especially during initiation of Hydrocodone Polistirex and Chlorpheniramine Polistirex therapy or when used in patients at higher risk [see Warnings and Precautions (5.2)].
Accidental Ingestion
Accidental ingestion of even one dose of Hydrocodone Polistirex and Chlorpheniramine Polistirex, especially by children, can result in a fatal overdose of hydrocodone [see Warnings and Precautions (5.2)].
Risk of Medication Errors
Ensure accuracy when prescribing, dispensing, and administering Hydrocodone Polistirex and Chlorpheniramine Polistirex. Dosing errors can result in accidental overdose and death. Always use an accurate milliliter measuring device when measuring and administering Hydrocodone Polistirex and Chlorpheniramine Polistirex [see Dosage and Administration (2.1), Warnings and Precautions (5.5)].
Cytochrome P450 3A4 Interaction
The concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex in patients taking a CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.7), Drug Interactions (7.2, 7.3)].
Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex in patients taking benzodiazepines, other CNS depressants, or alcohol [see Warning and Precautions (5.8), Drug Interactions (7.5)].
Interaction with Alcohol
Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking Hydrocodone Polistirex and Chlorpheniramine Polistirex. The co-ingestion of alcohol with Hydrocodone Polistirex and Chlorpheniramine Polistirex may result in increased plasma levels and a potentially fatal overdose of hydrocodone [see Warnings and Precautions (5.8) and Drug Interactions (7.1)].
Neonatal Opioid Withdrawal Syndrome
Hydrocodone Polistirex and Chlorpheniramine Polistirex is not recommended for use in pregnant women [see Use in Specific Populations (8.1)]. Prolonged use of Hydrocodone Polistirex and Chlorpheniramine Polistirex during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If Hydrocodone Polistirex and Chlorpheniramine Polistirex is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.13)].
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME
See full prescribing information for complete boxed warning.
Hydrocodone Polistirex and Chlorpheniramine Polistirex exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor closely for these behaviors and conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or when used in patients at higher risk. (5.2)
Accidental ingestion of Hydrocodone Polistirex and Chlorpheniramine Polistirex, especially by children, can result in a fatal overdose of hydrocodone. (5.2)
Ensure accuracy when prescribing, dispensing, and administering Hydrocodone Polistirex and Chlorpheniramine Polistirex. Dosing errors can result in accidental overdose and death. (2.1, 5.5)
Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex in patients taking CYP3A4 inhibitors or inducers. (5.7, 7.2, 7.3)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex in patients taking benzodiazepines, other CNS depressants, or alcohol. (5.8, 7.5)
Instruct patients not to consume alcohol or any products containing alcohol while taking Hydrocodone Polistirex and Chlorpheniramine Polistirex because co-ingestion can result in fatal plasma hydrocodone levels. (5.8, 7.1)
Hydrocodone Polistirex and Chlorpheniramine Polistirex is not recommended for use in pregnant women. Prolonged use of Hydrocodone Polistirex and Chlorpheniramine Polistirex during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If Hydrocodone Polistirex and Chlorpheniramine Polistirex is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. (5.13, 8.1)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 1 approved generic application on the market
Chlorpheniramine / hydrocodone questions
How much does chlorpheniramine / hydrocodone cost without insurance?
Pharmacies pay about $54.69 for 115 mL of chlorpheniramine / hydrocodone 1.6 mg/mL / 2 mg/mL (12 hr) extended release suspension ($0.4756 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $73.39. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is chlorpheniramine / hydrocodone in shortage?
No shortage is reported for chlorpheniramine / hydrocodone right now. We check the national shortage list every day.
Has chlorpheniramine / hydrocodone been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the chlorpheniramine / hydrocodone label last change?
The official label was last updated on February 17, 2026 (version 27). See what changed.
Talk about chlorpheniramine / hydrocodone
No comments yet. Questions, tips, what worked for you - start the conversation.